Return to content in this issue

Safety of new MRNA Vaccines Against COVID-19 in Severe Allergic Patients

Rojas-Pérez-Ezquerra P^1,2*, Crespo Quirós J^1,2*, Tornero Molina P^1,2, Baeza Ochoa de Ocáriz ML^1,2,3, Zubeldia Ortuño JM<sup>1,2,3

1</sup>Allergy Service. Hospital General Universitario Gregorio Marañón. Madrid, Spain.
²Gregorio Marañón Health Research Institute (IiGSM). Madrid, Spain.
³Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain.
*These authors contributed equally to this work.

J Investig Allergol Clin Immunol 2021; Vol. 31(2)
doi: 10.18176/jiaci.0683

• Abstract
• Supplemental Materials

Key words: Anaphylaxis, COVID-19 pandemic, Polyethilene glycol, PEG 2000, mRNA vaccines

	Title	Type	Size
	doi10.18176_jiaci.0683_material-suppl.pdf	pdf	399.94 Kb